A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Trial Summary
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: